Cargando…

Why promoting a COVID-19 vaccine booster dose?

Detalles Bibliográficos
Autores principales:	Loubet, Paul, Laureillard, Didier, Martin, Aurélie, Larcher, Romaric, Sotto, Albert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Société française d'anesthésie et de réanimation (Sfar). Published by Elsevier Masson SAS. 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8675238/ https://www.ncbi.nlm.nih.gov/pubmed/34924154 http://dx.doi.org/10.1016/j.accpm.2021.100967

Ejemplares similares

Use of short message service in at-home COVID-19 patient management
por: Loubet, Paul, et al.
Publicado: (2020)

What a second booster dose of mRNA COVID-19 vaccines tells us
por: Loubet, Paul, et al.
Publicado: (2022)

Effect of Tocilizumab on Mortality in Patients with SARS-CoV-2 Pneumonia Caused by Delta or Omicron Variants: A Propensity-Matched Analysis in Nimes University Hospital, France
por: Laffont-Lozes, Paul, et al.
Publicado: (2023)

COVID-19 vaccine equity and booster doses
por: The Lancet Infectious Diseases
Publicado: (2021)

Clinical Features and Outcomes of Enterococcal Bone and Joint Infections and Factors Associated with Treatment Failure over a 13-Year Period in a French Teaching Hospital
por: Martin, Aurélie, et al.
Publicado: (2023)

Clinical factors associated with peripherally inserted central catheters (PICC) related bloodstream infections: a single centre retrospective cohort
por: Barrigah-Benissan, Koko, et al.
Publicado: (2023)

COVID-19-associated mucormycosis: Looking for the culprit!
por: Larcher, Romaric, et al.
Publicado: (2021)

Last resort beta-lactam antibiotics for treatment of New-Delhi Metallo-Beta-Lactamase producing Enterobacterales and other Difficult-to-Treat Resistance in Gram-negative bacteria: A real-life study
por: Larcher, Romaric, et al.
Publicado: (2022)

Traitement par tocilizumab des patients présentant une COVID-19 sévère ou critique due au variant Delta ou Omicron du SARS-CoV-2 : étude prospective monocentrique en vie réelle
por: Laffont, P., et al.
Publicado: (2022)

Usefulness of dynamic regression time series models for studying the relationship between antimicrobial consumption and bacterial antimicrobial resistance in hospitals: a systematic review
por: Laffont-Lozes, Paul, et al.
Publicado: (2023)

Outcomes of Beta-Lactam Allergic and Non-Beta-Lactam Allergic Patients with Intra-Abdominal Infection: A Case–Control Study
por: Naciri, Tayma, et al.
Publicado: (2022)

The COVID-19 Vaccine: Why Should I Get the Vaccines and the Boosters?
por: Zanwar, Preeti Pushpalata, et al.
Publicado: (2023)

Patients’ Perception and Knowledge about Influenza and Pneumococcal Vaccination during the COVID-19 Pandemic: An Online Survey in Patients at Risk of Infections
por: Loubet, Paul, et al.
Publicado: (2021)

Myopericarditis After COVID-19 Booster Dose Vaccination
por: Sharff, Katie A., et al.
Publicado: (2022)

The third booster vaccination dose against COVID-19: indication for circulating SARS-CoV-2 variants
por: Rahimi, Farid, et al.
Publicado: (2021)

An Assessment of the Bivalent Vaccine as a Second Booster for COVID-19
por: Gupta, Sneh Lata, et al.
Publicado: (2022)

Booster or additional vaccination doses in patients vaccinated against COVID-19
por: García-Botella, Alejandra, et al.
Publicado: (2021)

COVID-19 booster doses in pregnancy and global vaccine equity
por: Kalafat, Erkan, et al.
Publicado: (2022)

Safety of seven COVID-19 vaccine booster doses
Publicado: (2021)

Interim statement on covid-19 vaccine booster doses
Publicado: (2021)

Interim statement on covid-19 vaccine booster doses
Publicado: (2021)

Covid-19 Boosters — Where from Here?
por: Offit, Paul A.
Publicado: (2022)

Booster Doses and Prioritizing Lives Saved
por: Patel, Minal K.
Publicado: (2021)

COVID-19 vaccine boosters: What do we know so far?
por: Kherabi, Yousra, et al.
Publicado: (2021)

Willingness to Receive the Booster COVID-19 Vaccine Dose in Poland
por: Rzymski, Piotr, et al.
Publicado: (2021)

Efficacy of COVID-19 vaccine booster doses in older people
por: Mattiuzzi, Camilla, et al.
Publicado: (2022)

Booster doses for inactivated COVID-19 vaccines: if, when, and for whom
por: Croda, Julio, et al.
Publicado: (2022)

Importance of the COVID-19 Vaccine Booster Dose in Protection and Immunity
por: Abdollahi, Alireza, et al.
Publicado: (2022)

Efficacy of the Second COVID-19 Vaccine Booster Dose in the Elderly
por: Mattiuzzi, Camilla, et al.
Publicado: (2023)

Assessing the acceptability of COVID‐19 vaccine and its booster dose
por: Mubarak, Sawsan, et al.
Publicado: (2023)

The pros and cons of the second booster dose of the COVID-19 vaccine
por: Mostafavi, Ehsan
Publicado: (2022)

Digital tablets to improve quality of life of COVID-19 older inpatients during lockdown
por: Goulabchand, Radjiv, et al.
Publicado: (2020)

First report of cavitary pneumonia due to community-acquired Acinetobacter pittii, study of virulence and overview of pathogenesis and treatment
por: Larcher, Romaric, et al.
Publicado: (2017)

COVID vaccine booster doses for omicron variants
por: Burki, Talha
Publicado: (2022)

Willingness to pay for and willingness to vaccinate with the COVID-19 vaccine booster dose in China
por: Zhou, Hui Jun, et al.
Publicado: (2022)

Coronavirus Vaccination and Mortality in the Omicron Outbreak in Iran: Mortality Reduction due to Attenuated Pathogenicity and Booster Vaccine Doses
por: Shamabadi, Ahmad, et al.
Publicado: (2022)

Prognostic value of an automated thrombin generation assay in COVID-19 patients entering hospital: A multicentric, prospective observational study
por: Gris, Jean-Christophe, et al.
Publicado: (2023)

Drivers of and Barriers to COVID-19 Vaccine Booster Dose Acceptance in Indonesia
por: Harapan, Harapan, et al.
Publicado: (2022)

Cost effectiveness of fractional doses of COVID-19 vaccine boosters in India
por: Du, Zhanwei, et al.
Publicado: (2023)

COVID-19 Vaccine Booster Dose Acceptance among Older Adults
por: Sezerol, Mehmet Akif, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nvc6efplmnagg7aou0cfhnbe56